Bimatoprost solution 0·03% topical application to the eyelid margin for the treatment of eyelash hypotrichosis

The document discusses a study by Glaser et al. from May 2015 on the efficacy and safety of topical bimatoprost solution 0.03% for treating eyelash hypotrichosis, which is a condition of having abnormally sparse eyelashes. The study was a prospective, multicentre, double-blind, randomized, parallel-group study that included an intent-to-treat population. The results showed that bimatoprost was significantly more effective than the vehicle (placebo) with 4-month response rates of 40.2% and 37.5% versus 6.8% and 18.2% for the idiopathic and chemotherapy-induced eyelash hypotrichosis groups, respectively. The study was praised for its robust design and precise efficacy measurements, but the authors noted that it lacked a detailed background on natural eyelash growth, information on the timing of treatment initiation, and prechemotherapy photographs. Additionally, the study did not provide information on the type of chemotherapy received or concurrent treatments for scalp hair or eyebrow loss, which could have influenced the results. Despite these limitations, the study provided evidence of the efficacy of topical bimatoprost for eyelash hypotrichosis and suggested further research into its use as a prophylactic treatment during chemotherapy.